Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2013 Apr;41(4):354–366.e14. doi: 10.1016/j.exphem.2012.11.008

Gene set control analysis predicts hematopoietic control mechanisms from genome-wide transcription factor binding data

Anagha Joshi 1,∗, Rebecca Hannah 1, Evangelia Diamanti 1, Berthold Göttgens 1,∗∗
PMCID: PMC3630327  PMID: 23220237

Abstract

Transcription factors are key regulators of both normal and malignant hematopoiesis. Chromatin immunoprecipitation (ChIP) coupled with high-throughput sequencing (ChIP-Seq) has become the method of choice to interrogate the genome-wide effect of transcription factors. We have collected and integrated 142 publicly available ChIP-Seq datasets for both normal and leukemic murine blood cell types. In addition, we introduce the new bioinformatic tool Gene Set Control Analysis (GSCA). GSCA predicts likely upstream regulators for lists of genes based on statistical significance of binding event enrichment within the gene loci of a user-supplied gene set. We show that GSCA analysis of lineage-restricted gene sets reveals expected and previously unrecognized candidate upstream regulators. Moreover, application of GSCA to leukemic gene sets allowed us to predict the reactivation of blood stem cell control mechanisms as a likely contributor to LMO2 driven leukemia. It also allowed us to clarify the recent debate on the role of Myc in leukemia stem cell transcriptional programs. As a result, GSCA provides a valuable new addition to analyzing gene sets of interest, complementary to Gene Ontology and Gene Set Enrichment analyses. To facilitate access to the wider research community, we have implemented GSCA as a freely accessible web tool (http://bioinformatics.cscr.cam.ac.uk/GSCA/GSCA.html).


Cell type–specific gene expression is an inherent property of all multicellular organisms and indeed represents a major determinant that underlies the generation of differentiated cell types with distinct functionality. Elucidating the molecular mechanisms controlling cell type–specific expression has the power to reveal fundamental insights into the regulatory circuitry controlling both human and model organism development. Moreover, identification of control mechanisms in normal cells provides potential avenues for manipulating cellular fates, as exemplified by the recent explosion in cellular reprogramming studies [1]. It also enables the rational design of new therapies aiming to revert abnormal pathological cellular states back to their normal condition [1].

The blood or hematopoietic system has long been recognized as a powerful model system for studying cell type–specific gene expression [2]. Within the blood system, more than 10 distinct mature hematopoietic lineages (e.g., red blood cells, T cells, B cells) are generated from pluripotent hematopoietic stem cells (HSCs) via a sequence of intermediate progenitors, often represented as a lineage differentiation tree. Both the mature lineages as well as the various immature blood stem and progenitor populations can be purified based on the expression of combinations of specific cell surface markers, thus enabling powerful studies of cellular differentiation.

Transcription factors have long been recognized as major regulators of hematopoietic cell type specification [3–6]. To understand the mechanisms underlying cell type specification by transcription factors, it will be essential to identify their transcriptional targets. An important advancement in this research area was provided by the introduction of chromatin immunoprecipitation (ChIP) coupled to massively parallel sequencing (ChIP-Seq), which allows genome scale identification of all DNA sequences (regions) bound by a given transcription factor (TF) in a given cell type [7]. The technique has been rapidly adopted with over 100 individual studies now deposited in public databases for the murine hematopoietic system alone. This wealth of new data represents unprecedented opportunities to unravel the transcriptional control mechanisms that mediate expression of specific sets of genes within the various hematopoietic cell lineages [8].

Gene ontology [9] overrepresentation analysis provides information on various types of functional categories enriched within a given gene set of interest [10] and GSEA determines whether a gene set of interest shows statistically significant expression differences between two or more cell types [11]. However, neither of these approaches explicitly links a gene set to transcriptional control mechanisms. In this study, we report a new computational framework for linking gene sets with transcriptional control, called Gene Set Control Analysis (GSCA). Unlike previous algorithms developed to provide functional enrichment [10], GSCA links gene sets to likely upstream regulators responsible for coordinated expression. By exploiting multiple transcription factor binding patterns from genome-wide ChIP-Seq studies, GSCA can provide previously unattainable insights into possible transcriptional control mechanisms operating in both normal and malignant cells. To gain insights into combinatorial control mechanisms (i.e. multiple transcription factors occupying the same binding site in a gene locus), we further developed a novel tool called combinatorial-GSCA (C-GSCA). Through integrated analysis of 142 blood-specific ChIP-Seq binding datasets, C-GSCA identifies likely combinatorial transcriptional control mechanisms by revealing TF cooccupancy patterns specifically associated with gene regulatory elements from a given gene set. A web-based implementation of GSCA and C-GSCA allows user-friendly access for the wider research community, and thus provides a substantial new addition to the bioinformatic toolbox for hematopoietic gene set analysis.

Methods

ChIP-seq compendium

Binding events for 35 transcription factors in seven major hematopoietic lineages were obtained from Hannah et al. [8]. Sixty new ChIP datasets from 18 publications and ENCODE murine datasets were analyzed, starting from the raw data set in each case, and peaks were identified in each sample using the protocol described previously [8]. A supplementary website (http://bioinformatics.cscr.cam.ac.uk/BLOOD_compendium_PUBLISHED.html) lists the number of peaks, reference, and peak calling method for each of the ChIP dataset. All binding events were mapped to genes using the same protocol described previously [12]. Binding events in the promoter and gene body were associated to the corresponding gene, whereas intergene peaks were associated to the nearest gene on either side within 50 kb, such that each peak is assigned to at most two genes.

Tissue-specific enhancer elements in mouse were downloaded from [13] and p value was calculated for overlap between each of the 61 tissue-specific enhancer regions and blood-specific regulatory regions [8] using a hyper-geometric test (Supplementary Table 1, online only, available at www.exphem).

GSCA method

Of 270,261 genomic regions bound by at least one TF (N), for a set of user-defined genes, we calculate the number of genomic regions mapped to the genes (n). For each ChIP-Seq ChIP dataset, the number of peaks (m) near user defined genes (k) is calculated. The p value is calculated using a hypergeometric test (Fischer exact test).

cGSCA method

A matrix of binding events with 270,261 genomic regions as rows and overrepresented ChIP-seq data sets (K) from GSCA step as columns is generated. The ChIP-seq data sets (K columns) are then clustered using a hierarchic clustering with Pearson's correlation coefficient as a distance measure.

Reference data set

Gene sets for 80 clusters of tightly coexpressed genes (their induction patterns) in 38 hematopoietic cell types were obtained from Novershtern et al. [14]. Human genes were mapped to orthologous mouse genes using MGI mammalian orthology (http://www.informatics.jax.org/orthology.shtml). We calculated the p value for each gene set with respect to each signature cluster using a hypergeometric test. We used the number of Novershtern clusters significantly overrepresented (Bonferroni corrected p < 0.001) for one or more transcription factor targets as a measure to evaluate performance while comparing different methods.

Gene expression datasets

Nine gene expression signatures (d-erythroid, differentiated, d-lymphoid, d-myeloid, r-myelolymphoid, s-erythroid, s-mpp, s-myelolymphoid, and stem) were obtained from [15]. Differentially expressed genes in various leukemia datasets were downloaded from their respective publications. Gene lists were then interrogated against the ChIP-seq compendium using both GSCA and C-GSCA.

GSCA web tool

The GSCA output was produced using R, and the web user interface of the application was done using Perl/CGI/HTML. R commands are executed through the perl–cgi script to produce the image. The web tool can be accessed at the following URL: http://bioinformatics.cscr.cam.ac.uk/GSCA/GSCA.html.

Results

Definition of a candidate regulatory genome in mouse hematopoiesis

We recently reported a compendium of more than 50 TF ChIP-Seq experiments in mouse blood cells collected from publicly available datasets [8]. We have doubled the compendium by adding 60 new ChIP datasets from 18 recently published studies [16–33] and ENCODE murine unpublished datasets to obtain genome-wide binding patterns for 53 unique transcription factors in 15 major blood lineages and three types of leukemia (Table 1). TF-bound peaks were determined for all new datasets using the same parameters as before [8], which resulted in a total of 270,261 genomic regions bound by at least one transcription factor. When added together, these 270,261 regions corresponded to 936 Mb, thus constituting 5.78% of the mouse genome. ChIP-Seq samples of the same transcription factor in related cell types were merged together to provide a consolidated set of 78 samples (Table 1).

Table 1.

Seventy-eight ChIP-Seq binding peak files covering 53 unique transcription factors in 15 major blood lineages

Cell type Transcription factors
Lymphocytes
 B cells E2A, Ebf, Foxo1, Oct2, Pax5, Pu.1
 T cells Gata3, Fli1, Pu.1, Stat3, Stat4, Stat5, Stat5a, Stat5b, Stat6, Tbet
 Thymocytes Cbfb, Rag2, Ring1b, Runx1
Progenitors
 HPC Gata2, Ldb1, Scl
 HPC7 Erg, Fli1, Gata2, Gfi1b, Lmo2, Meis1, Pu.1, Lyl1, Runx1, Scl
 EML Runx1, Tcf7
 Erythroid progenitors Gata1, Gata2, Smad1
 MK progenitors Cbfb, Ring1b, Runx1
 Myeloid progenitors Myb
 Pro B cells Ebf1, Smad1
Myeloerythroid
 MK (megakaryocytes) Gata1
 Macrophages Cebpα, Cebpβ, P65, Pparg, Pu.1, Stat1
 Erythroid Eto2, Gata1, Ldb1, Mtgr1, Pu.1, Scl
Leukemias
 Leukemia Notch1
 MLL leukemia Af9
 T cell leukemia RbpJ
 T-ALL Notch1
 MEL Cmyb, Cmyc, Chd2, Gata1, JunD, MafK, Max, Mxi1, NelfE, Scl, Smc3, Tbp, Usf2

Pennacchio et al. [13] developed a phylogenetic conservation and motif based approach to predict tissue specific enhancers, which allowed them to annotate ∼5,500 high-confidence mouse tissue-specific enhancers for 61 murine tissue types by integrating tissue-specific expression data, conservation information, and cis-regulatory motifs. Only 4 of these 61 tissues corresponded to hematopoietic cells, and predicted only enhancers for those four tissues showed significant overlap with our ChIP-enriched regions (B220+ B cells, p = 1.9e-10; CD4+ T cells, p = 1.4e-4; CD8+ T cells, p = 7.0e-7; lymph node, p = 1.0e-4; see Supplementary table 1). This analysis therefore supports the validity of a compendium built on TF binding events in hematopoietic cells.

A new GSCA tool matches weighted TF-peak lists to gene sets

We next explored whether our blood-specific TF ChIP-Seq peak catalogue could be used to predict transcriptional control mechanisms that may regulate the coordinated expression of a given set of genes. Computational tools for the identification of statistically significant overlaps between a given gene set and peak regions from single ChIP-Seq experiments have been described previously [34,35]. However, these tools do not exploit the ever-increasing number of datasets for multiple TFs in the same or related cell types.

Novershtern et al. [14] reported gene expression profiles in 38 distinct purified populations of human hematopoietic cells ranging from hematopoietic stem cells, through multiple progenitor and intermediate maturation states, to 12 terminally differentiated cell types. Using the Module Networks algorithm [36], they identified 80 modules or gene sets of tightly coexpressed genes with distinct expression patterns and enrichment for specific biological functions, which they termed induction patterns. When we used the 80 Novershtern modules as gene sets, 37 of 80 gene sets (Supplementary Table 2, online only, available at www.exphem) showed a statistically significant correlation with one or more TF peak files from our compendium when using the previously described ChIP Enrichment Analysis (ChEA) [34] and Csan [35] tools. Of note, there was a good overlap between the cell type used for ChIP-Seq and the expression/induction patterns as annotated by Novershtern et al. (Supplementary Table 2). For example, gene set 727 with induction pattern “Late Erythroid” was associated with Eto2 in Erythroid, Scl, and Ldb1 in HSCs and Scl in MELs, and gene set 979 overrepresented for “immune response” genes with induction pattern “Late MYE” was associated with Cebpα, Cebpβ, P65, Pparg, and Stat1 in macrophages.

Because the ChEA [34] and Csan [35] tools could associate candidate upstream regulators to less than half of the 80 Novershtern gene sets, we set out to develop an alternative approach by incorporating the concept of weighted peak-to-gene mapping recently reported as part of the Genomic Regions Enrichment of Annotations Tool (GREAT) [37]. GREAT links a list of ChIP-Seq peak regions to gene lists with particular functional significance and unlike previous approaches incorporates binding sites not only in the promoter region of a gene. Taking inspiration from this approach, we developed a new tool by mapping each peak to its nearest gene within 50 kb and then considering the number of binding events in each gene locus to calculate the significance of association between a gene locus and a given upstream regulator. (Essentially this is the reverse of GREAT, which associates peaks with genes, whereas our new procedure associates genes with peaks). Specifically, our new tool determines the number of binding events in the loci of genes of interest for each ChIP dataset (Fig. 1A, red arrows), and then calculates a p value using a simple hypergeometric test. Datasets with statistically significant overlaps (corrected p value cut-off <0.001) are then selected by interrogating all ChIP datasets independently against the gene list (Fig. 1B). When applied to the 80 gene modules from Novershtern et al. [14], our new tool reported significant associations with ChIP-Seq peaks for 65 gene modules (Supplementary Table 2, online only, available at www.exphem), which corresponds to 81% of all gene sets compared with only 46% using the previously reported ChEA and Cscan tools. Incorporation of weighted gene lists therefore results in a significant increase in the percentage of gene modules that can be linked to candidate upstream regulators. We named this new approach Gene Set Control Analysis, or GSCA. Only 61% of all Novershtern gene sets (49 of 80 gene modules) were enriched when the binding events only in promoters were selected, thus highlighting the likely importance of binding to nonpromoter regions, which compose 57% of all binding events in our datasets.

Figure 1.

Figure 1

Schematic representation of the Gene Set Control Analysis (GSCA) protocol. For a given gene set of interest (red arrows), the number of peaks in gene loci is determined and a p value is calculated using a hypergeometric test. The TFs from overrepresented ChIP datasets (corrected p < 0.001, yellow bars in the figure) are then reported as candidate upstream transcriptional regulators. (For interpretation of the reference to color in this figure legend, the reader is referred to the web version of this article.)

GSCA correlates relevant combinations of transcription factors with hematopoietic gene sets

To investigate the potential biological relevance of the candidate upstream regulatory transcription factors matched with the 65 Novershtern gene sets by GSCA, we again used the induction patterns defined by Novershtern et al. as a measure of lineage-specific expression. The majority of gene sets (97%) showed good correspondence between the induction patterns and the cell types in which the TFs had been chipped (Supplementary Table 3, online only, available at www.exphem).

For example, gene sets 667 and 829 (enriched for T cell receptor activity) were associated by GSCA with Stats and Gata3 in T cells, whereas gene sets 649 and 961 (enriched for B cell receptor activity) were associated with Pu.1, E2A, and Pax5 in B cells. Gene set 721 (involved in inflammatory and antibacterial response) was linked by GSCA with Cebpα, Cebpβ, P65, Pu.1, and Stat1 in macrophages. Gene sets 727 and 889 with Late Ery induction pattern (enriched for protein amino acid glycosylation and blood group antigen functional annotations) significantly overlapped only with targets of Eto2, Gata2, Ldb1, Mtgr1, and Scl in erythroid cells. Taken together therefore, there is good concordance between the induction patterns of Novershtern gene sets and the matching ChIP-Sequencing TF datasets identified by GSCA.

Combinatorial regulatory pattern discovery from multi factor ChIP-Seq data

Compared with previous tools, our new GSCA tool performs better by associating gene lists with ChIP-Seq peaks by calculating weighted associations between factors and genes based on the number of binding events within a gene locus. However, all individual ChIP-Seq datasets are treated independently, thus making it difficult to infer whether two overrepresented transcription factors work combinatorially (e.g. whether they show statistically significant co-occupancy of the same regulatory regions), rather than binding to overlapping sets of gene loci, but using distinct cis-regulatory regions. To address this issue of combinatorial binding, we developed a new tool called combinatorial GSCA (C-GSCA), and then applied this new tool to our hematopoietic ChIP-Seq compendium. For a given gene list, we first run GSCA to select the TFs showing overrepresented binding. Assuming that m TFs are selected out of 78 ChIP-seq datasets, we generate a binary matrix (n × m) of m columns representing the m ChIP datasets and n rows representing the genomic regions occupied by two or more of the m TFs, with 1s and 0s indicating the presence or absence of binding, respectively. We filter genomic regions bound by only one factor (∼16% of genomic regions; Supplementary Table 2, online only, available at www.exphem) because they are not informative in terms of combinatorial control mechanisms. We then perform hierarchical clustering of n overrepresented ChIP datasets using Pearson's correlation coefficient as a distance measure. Unlike GSCA, all overrepresented ChIP datasets are considered together, making the prediction of combinatorial control feasible (Fig. 2).

Figure 2.

Figure 2

(A) Schematic representation of combinatorial Gene Set Control Analysis (cGSCA). A binary matrix of combinatorial binding patterns is generated using the overrepresented ChIP datasets from GSCA. (B) A hierarchical tree is then generated by clustering similar patterns. Color figure online.

Using ChIP-Seq analysis of 10 transcription factors in the hematopoietic progenitor cell line HPC7, we have shown previously that combinatorial interactions between a heptad of TFs (SCL, LYL1, LMO2, GATA2, RUNX1, ERG, and FLI-1) were overrepresented in the loci of genes specifically expressed in HSPCs and therefore associated with gene sets specifically expressed in HSCs [12]. When the heptad-bound genes were interrogated using GSCA, 49 of 78 ChIP-Seq datasets were enriched, thus identifying multiple new transcription factors as candidate upstream regulators in addition to the seven factors (Supplementary Figure 1, online only, available at www.exphem). Using C-GSCA, these 49 datasets could be split into four cell type–specific groups of T cells, macrophages, HSCs, and erythroid (Supplementary Figure 1, online only, available at www.exphem). This observation suggests that gene loci bound by the heptad in blood stem and progenitor cells not only include genes specifically expressed in HSCs, but could also include a subset of genes affiliated with various different hematopoietic differentiation programs—an observation that would be consistent with the concept of lineage priming developed in the 1990s [38]. These results suggested that the C-GSCA procedure outlined here may be useful more generally to associate hematopoietic gene sets to upstream regulators and thus able to predict combinatorial control mechanisms driving the expression of a given gene set.

We next applied the new C-GSCA tool to all 80 hematopoietic gene sets from the Novershtern et al. study [14], which allowed us to associate 65 of the 80 Novershtern gene sets overrepresented for ChIP datasets using GSCA for combinatorial TF signatures. For example, Novershtern gene set 583 with induction pattern “Late Ery + T/B cell + GRAN” is associated with entirely different sets of transcription factors in two different cell types, because it was linked with Gata1, Gata2, Scl, and Smad1 in erythroid progenitors, and Rag2 in thymocytes, Max, Mxi1, and Tbp in mouse erythroleukemia (MEL) (Fig. 3A). Similarly, gene set 745 with induction pattern “NK + T cell” is linked with Myb in myeloid progenitors and Stat3, Stat4, and Stat5 in T cells (Fig. 3B). Indeed, more than 60% (40 of 65) of the overrepresented Novershtern gene sets with matched upstream regulators were linked with more than one combinatorial pattern (Supplementary Table 3, online only, available at www.exphem). Therefore, unlike the GSCA approach (Fig. 1), C-GSCA has the potential to identify distinct subsets of candidate upstream regulators for a given gene set (Fig. 2).

Figure 3.

Figure 3

Figure 3

(A) Overrepresented regulators determined using GSCA (left) and C-GSCA (right) for gene module 583 from Novershtern et al. [14], with “Late Ery + T/B cells + GRAN” induction pattern. Unlike GSCA, C-GSCA can separate overrepresented independent binding patterns in different cell types (Gata1, Gata2, and Smad1 Erythroid progenitors and Max, Mxi1, and Tbp in MELs in this case). (B) Overrepresented regulators determined using GSCA (left) and C-GSCA (right) for gene module 745 from Novershtern et al. [14] with “NK + T cell” induction pattern. C-GSCA is able to separate combinatorial patterns in T cells and myeloid progenitors.

GSCA web tool

As GSCA and C-GSCA provide potentially powerful ways of predicting candidate upstream regulators for a given list, we developed a web tool to facilitate gene set control analysis for the wider community (http://bioinformatics.cscr.cam.ac.uk/GSCA/GSCA.html). In this section we provide a brief explanation of the functionality of the GSCA web tool using a recent transcriptome analysis of murine HSCs and early multipotent, bipotent, and unipotent progenitors [15], which reported nine gene expression signatures ranging from those characteristic for the most immature HSCs to those affiliated with differentiation into the individual hematopoietic lineages. We interrogated these nine experimentally obtained gene expression signatures using the GSCA web tool. Eight of these nine mouse stem–progenitor gene signatures showed significant overlap with multiple ChIP-Seq data sets, thus providing an independent test case to examine the biological relevance of predicted combinatorial regulatory signatures in addition to testing the functionality of the web tool (Supplementary Figure 3, online only, available at www.exphem). Figure 4A shows a screenshot of the web tool in which users can paste a query gene list or upload it from a file (human or mouse).

Figure 4.

Figure 4

(A) Screen shot of Gene Set Control Analysis (GSCA) web tool with an option to either paste user defined gene list or upload from file, and to select method (GSCA or C-GSCA). (B) GSCA and C-GSCA output for stem signature dataset from Ng et al. [15] showing two cell type–specific distinct combinatorial patterns.

Upon choosing GSCA, a gene list of interest is interrogated against 78 ChIP-Seq datasets across 15 blood cell types. GSCA calculates the significance of overlap between each ChIP-Seq dataset and the gene set of interest and displays all ChIP-Seq datasets, with those showing enrichment in yellow color. For example, the self-renewing signature (stem signature from Ng et al. [15]) is provided as a test dataset for the users and shows statistically significant overlap with multiple transcription factors in HPC7 and progenitors. When the same stem signature gene list is analyzed using C-GSCA, the overrepresented ChIP datasets are clustered into two distinct cell type specific clusters HPC7 and MK progenitors (Fig. 4B). Six of the seven transcription factors in the HPC7 cluster overlap with the heptad signature—a binding pattern that we have previously shown is overrepresented in the loci of genes specifically expressed in HSPCs and therefore associated with gene sets specifically expressed in HSCs [12]. Similarly, the gene signature associated with the third wave of the myeloid lineage program (d-my signatures) from Ng et al. [15] shows statistically significant overlap with two combinatorial binding events, Cebpα, Cebpβ, Stat1, P65, and Pu.1 in macrophages and Myb in myeloid progenitors. In addition to showing the functionality of the web tool, these results suggest that combinatorial control signatures generated by C-GSCA have the potential to provide insights into combinatorial transcriptional control mechanisms, and that the GSCA web tool provides access to this type of analysis to the wider community.

GSCA analysis of gene sets associated with hematologic malignancies

We have shown that GSCA can be used to link lineage-specific gene sets to combinations of candidate upstream regulatory TFs, and these associations are consistent with expectations based on current knowledge of regulatory control within hematopoiesis. This consistency attests to the potential robustness of the GSCA approach and suggests that it may also be useful to reveal biological insights into transcriptional programs operating in malignant hematopoietic cells, where diagnostic or prognostic gene sets have been derived for many types of leukemia, yet the combinations of TFs driving expression of these gene sets remain largely unknown. We therefore explored the utility of GSCA for linking leukemic gene sets with candidate upstream regulators.

We first analyzed a gene set recently reported by McCormack et al. [39], in which the investigators showed that overexpression of Lmo2 in T-lymphoid progenitors induced a preleukemic state characterized by extensive self-renewal capacity. When the authors performed comparative gene expression profiling of normal and LMO2 expressing thymocytes, they noted upregulation of several HSC specific genes and suggested that ectopic expression of Lmo2 might activate an HSC specific transcription program. To test this hypothesis further, we analyzed the list of genes upregulated in Lmo2 transgenic DN thymocytes [39] by GSCA. This analysis suggested that the LMO2 overexpression gene set was under the transcriptional control of stem cell transcription factors such as Scl, Gata2, Runx1, Fli1 and Erg and also showed a strong overlap with LMO2 binding itself in non-leukemic progenitor cells.

We next analyzed gene expression profiling data generated as part of a recent study investigating transcriptional programs downstream of mixed lineage leukemia (MLL) transformation in mouse models of acute myeloid leukemia (AML) [40]. Expression analyses following MLL-AF9 withdrawal had prompted the authors to propose a model whereby MLL-AF9 enforces a Myb-coordinated program of aberrant self-renewal that involves genes linked to leukemia stem cell potential and poor prognosis in human AML patients. Of note, when we analyzed the genes downregulated following MLL-AF9 withdrawal by GSCA, we observed statistically significant overlaps with the two Myb ChIP-Seq datasets in our compendium (Fig. 5A). In addition, GSCA also recovered associations with MAX and the MAX interacting protein MXI1, both of which have also been linked to a range of human cancers [41]. GSCA analysis therefore not only corroborated the findings by Zuber et al. [40]; it also provided additional hypotheses on likely mechanisms that might control transcriptional programs downstream of MLL-AF9 in AML.

Figure 5.

Figure 5

(A) Overrepresented regulators determined by C-GSCA for genes down regulated after MLL-AF9 withdrawal from Zuber et al. [40]. C-GSCA supports the notion that AF9 induces an Myb coordinated response. (B) Overrepresented regulators determined by C-GSCA for genes positively correlated with LSC frequency from Somervaille et al. [42]. C-GSCA identified cMyc and several other transcription factors to be overrepresented.

The final leukemic gene set analyzed by GSCA was taken from a 2009 study of the transcriptional programs in leukemic stem cells [42]. Comprehensive gene expression profiling analysis had lead the authors to speculate that leukemia stem cells in an MLL-driven mouse model of AML are characterized by a transcriptional program shared with embryonic rather than adult stem cells. This conclusion was subsequently challenged when it was suggested that the overlap with embryonic stem cell transcriptional programs was the reflection for a shared dependence on c-MYC activity rather than related to the stemness phenotype of ES cells [43]. Analysis of the leukemia stem cell associated gene set from the Somervaille et al. [42] study by GSCA revealed a strong association with c-MYC ChIP-Seq datasets (Fig. 5B). However, there were also statistically significant associations with many additional ChIP-Seq datasets. GSCA analysis was therefore supportive of a role for c-MYC in the similarity between leukemic and embryonic stem cell expression signatures, but suggested that TFs more specifically expressed within blood cells also make important contributions to the leukemia stem cell transcriptional program. Of note, genes negatively associated with the leukemia stem cell phenotype in the study by Somervaille et al. [42] did not show the overlap with c-MYC, but it showed a distinct pattern of correlated ChIP-Seq datasets for the hematopoietic TFS, which interestingly contained several datasets for mature macrophages and was thus consistent with a relatively immature differentiation stage for the leukemia stem cells (Supplementary Figure 2, online only, available at www.exphem).

The application of GSCA to leukemic expression datasets supports the notion that integrated analysis of genome-wide transcription factor binding maps has significant potential as a new addition to the toolbox used by experimentalists to derive new hypothesis for experimental validation, which in the case of our current implementation of GSCA analysis would be geared specifically toward the identification of transcriptional mechanisms that control the behavior of normal and leukemic blood cells.

Discussion

Gene expression arrays have been used widely to characterize genes responsible for a particular cellular phenotype. The differentially expressed genes thus obtained can then be used for functional enrichment analysis. However, the important question of “What upstream regulatory mechanisms are responsible for the differential expression?” is not specifically addressed when using current approaches for gene set analysis, such as Gene Ontology or Gene Se Enrichment analysis tools.

As a result of the rapid progress in next-generation sequencing technology, ChIP-Seq analysis has become a favorite tool to investigate in vivo binding events because it offers higher resolution, less noise, and greater coverage compared with other techniques [44]. Nevertheless, the generation of genome-wide binding maps for multiple transcription factors across different cell types remains a formidable challenge for individual labs [45]. ChIP-Seq datasets from different labs can, however, be integrated at the computational level, which we recently demonstrated using 53 mouse ChIP-Seq experiments from different laboratories across the hematopoietic differentiation tree [8]. Since then, we have added 60 new ChIP datasets, thus more than doubling the size of the original compendium. In addition to highlighting a potentially major portion of the total regulatory genome involved in hematopoietic gene expression, a data compendium of this scale should have the potential to provide new insights into regulatory mechanisms governing gene sets of interest.

To explore this further, we developed GSCA to identify enriched combinatorial binding patterns of transcription factors regulating a given gene set. This method uses experimental binding evidence, keeping the cell type specific context, unlike prediction methods based on overrepresentation of cis-regulatory sequence motifs in the promoters [46]. Using 80 clusters of tightly coexpressed genes in 38 hematopoietic cell types [14], we demonstrated that the transcriptional control mechanisms predicted are biologically coherent, and that GSCA performs better than current methods. Of note, this analysis also demonstrated that GSCA can be used in a cross-species fashion, with human gene sets analyzed using a murine ChIP-Seq compendium in this particular instance. The rationale for this cross-species capability is provided by recent observations from ChIP-Seq data for the same transcription factor in multiple species where it was shown that, although a significant proportion of binding locations (peaks) are not conserved, there tends to be what was termed binding site turnover for these sites where loss of binding in one species is accompanied by gains elsewhere in the same gene locus in the other species [47]. The conserved and many of the nonconserved binding sites therefore map to the same gene loci, such as in human–mouse comparisons. Just as for many other gene set analysis tools, cross-species capability in GSCA is facilitated by the use of standard gene symbols that are standardized across mammals.

We further illustrated the utility of the GSCA tool to unravel potential regulatory mechanisms underlying a range of leukemia gene sets, thus suggesting potential future application of GSCA to build hypotheses to investigate transcriptional control mechanisms responsible for the expression of gene sets with diagnostic, prognostic, or therapeutic relevance. Finally, we built a web tool to facilitate similar analysis for the wider scientific community. Complementary to gene ontology functional overrepresentation analysis, GSCA calculates overrepresentation of binding events for a gene list of interest, thus predicting possible transcriptional control mechanisms.

Given the significant investment into several collaborative projects such as the ENCODE (Encyclopaedia of DNA Elements) and modENCODE (model organism ENCODE) initiatives [48,49], we are likely to witness a near exponential increase in ChIP-Seq datasets over the coming years. Although our current implementation of the GSCA web tool is geared toward predicting candidate upstream regulators within hematopoietic cells, the approach can be applied easily to other tissues when sufficient ChIP-Seq data become available.

Acknowledgments

A.J. is a recipient of a European Molecular Biology Organization long-term fellowship. Work in the authors' laboratories is supported by grants from Leukemia and Lymphoma Research, the Medical Research Council, Biotechnology and Biological Sciences Research Counsel, Cancer Research UK, Wellcome Trust, and the Leukemia and Lymphoma Society.

Author contributions: A.J. developed the GSCA software and performed analysis; R.L.H. collected and processed publicly available ChIP-Seq data; E.D. developed the web tool; B.G. designed the study and supervised the work; A.J. and B.G. wrote the manuscript.

Footnotes

Supplementary data related to this article can be found online at http://dx.doi.org/10.1016/j.exphem.2012.11.008.

Contributor Information

Anagha Joshi, Email: aj379@cam.ac.uk.

Berthold Göttgens, Email: bg200@cam.ac.uk.

Conflict of interest disclosure

No financial interest/relationships with financial interest relating to the topic of this article have been declared.

Supplementary data

Supplementary Figure 1.

Supplementary Figure 1

GSCA analysis of Heptad signature identified by Wilson et al. [12].

Supplementary Figure 2.

Supplementary Figure 2

Hierarchical maintenance of MLL myeloid leukemia stem cells uses a transcriptional program shared with embryonic rather than adult stem cells [42]. (A) Probe sets positively correlated with LSC frequency. (B) Probe sets negatively correlated with leukemia stem cell (LSC) frequency.

Supplementary Figure 3.

Supplementary Figure 3

GSCA analysis of eight of nine gene expression signatures identified by Ng et al. [15].

Supplementary Table 1.

The overlap between tissue specific enhancers identified by Pennacchio et al. [13] and the blood compendium showing that the enhancers in the compendium are highly blood specific

Tissue type Number of enhancers Overlap p value
adipose tissue 213 86 0.99995
Adrenal gland 176 47 1
Amygdala 218 24 1
B220+ B cells 212 158 1.91E-10
Bladder 225 48 1
Blastocysts 191 63 1
Bone 200 87 0.99795
Bone marrow 224 101 0.99466
Brown fat 224 47 1
CD4+ T cells 226 148 0.000149
CD8+ T cells 194 137 7.00E-07
Cerebellum 180 24 1
Cerebral cortex 190 29 1
Digits 263 56 1
Dorsal root ganglia 193 45 1
Dorsal striatum 193 30 1
Embryo day 10 171 58 1
Embryo day 6 167 68 0.99961
Embryo day 7 163 51 1
Embryo day 8 170 44 1
Embryo day 9 174 63 1
Epidermis 292 58 1
Eye 255 32 1
Fertilized egg 176 33 1
Frontal cortex 197 21 1
Heart 227 62 1
Hippocampus 201 30 1
Hypothalamus 183 25 1
Kidney 230 43 1
Large intestine 208 62 1
Liver 267 27 1
Lung 241 75 1
Lymph node 245 160 0.000102
Mammary gland 198 33 1
Med 192 40 1
Olfactory bulb 194 32 1
Oocyte 173 37 1
Ovary 192 46 1
Pancreas 211 45 1
Pituitary 187 34 1
Placenta 202 59 1
Preoptic 176 29 1
Prostate 221 49 1
Salivary gland 213 46 1
Skeletal muscle 224 44 1
Small intestine 259 65 1
Snout epidermis 275 51 1
Spinal cord lower 197 39 1
Spinal cord upper 196 26 1
Spleen 228 108 0.97033
Stomach 206 46 1
Substantia nigra 183 29 1
Testis 197 31 1
Thymus 194 111 0.15904
Thyroid 239 47 1
Tongue 289 51 1
Trachea 250 72 1
Trigeminal 193 30 1
Umbilical cord 223 44 1
Uterus 181 58 1
Vomeralnasal organ 252 66 1

Supplementary Table 2.

Thirty-seven gene sets of 80 with respective induction patterns from Novershtern et al. [14] found enriched using the method of Lachmann et al. [34] and Zambelli et al. [35]

Novershtern et al. clusters
Candidate upstream regulators
# Induction pattern Transcription factor Cell type
583 Late Ery + T/B cell + GRAN TCF7
GFI1B
SCL
MAX, MXI1, NELFE, TBP
ETS1
FLI1
RAG2
EML
Erythroid
HPC
MEL
MK progenitors
T cells
Thymocytes
607 TCF7
GFI1B, SCL
P65, PPARG
MXI1, NELFE
MYB
FLI1
RAG2, RING1B
EML
HPC7
Macrophages
MEL
Myeloid progenitors
T cells
Thymocytes
649 B cell E2A, EBF1, OCT2, PAX5, PU1
RUNX1
GFI1B, LDB1, MTGR1, PU1, SCL
SCL
FLI1, GATA2, MEIS1, PU1, SCL
CEBPA, CEBPB, P65, STAT1
CMYB, CHD2, JUND, MAFK, MAX, MXI1, NELFE, SCL
GATA1
CBFB, RING1B, RUNX1
AF9
MYB
EBF1, SMAD1
RBPJ
FLI1, GATA3, PU1, STAT3, STAT5A, STAT5B, STAT5, TBET
CBFB, RAG2, RUNX1
B cells
EML
Erythroid
HPC
HPC7
Macrophages
MEL
MK cells
MK progenitors
MLL leukemia
Myeloid progenitors
Pro B cells
T cell leukemia
T cells
Thymocytes
655 Mye LDB1, SCL
NELFE, SCL
HPC
MEL
661 Late Ery + T/B – cell + GRAN TCF7
NELFE
FLI1
RAG2
EML
MEL
T Cells
Thymocytes
667 T cell + NK RUNX1
GATA2, RUNX1
RUNX1
GATA3, STAT5A, STAT5B
CBFB, RUNX1
EML
HPC
HPC7
T Cells
Thymocytes
673 T/B cell E2A, EBF1, OCT2
GATA2, RUNX1, SCL
CEBPA, CEBPB, P65, PPARG
EBF1, SMAD1
FLI1, GATA3, PU1, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6
CBFB, RING1B, RUNX1
B cells
HPC7
Macrophages
Pro B cells
T cells
Thymocytes
685 Early Mye + T/B cell + GRAN RUNX1, TCF7
GFI1B, PU1
SCL
CEBPA, CEBPB, P65
CMYC, MAX, MXI1, NELFE, TBP
CBFB, ETS1, RUNX1
MYB
FLI1, STAT4, STAT5B, STAT6, TBET
CBFB, RAG2, RING1B, RUNX1
EML
Erythroid
HPC7
Macrophages
MEL
MK progenitors
Myeloid progenitors
T cells
Thymocytes
703 T/B cell RAG2 Thymocytes
715 Early Mye + T/B cell + GRAN RAG2 Thymocytes
721 Late MYE + DCs CEBPA, CEBPB, P65 Macrophages
727 Late Ery ETO2
LDB1, SCL
SCL
Erythroid
HPC
MEL
733 HSE + Early Mye RUNX1, TCF7
GATA1, GATA2
GFI1B, MTGR1, SCL
GATA2, GFI1B, LMO2, MEIS1, PU1, SCL
CEBPA, CEBPB, P65, STAT1
GATA1, MAFK, MXI1, NELFE, TBP
GATA1
GATA1, GATA2, RING1B
MYB
GATA3, STAT3, STAT5A, STAT5B, STAT5, STAT6, TBET
RAG2, RING1B, RUNX1
EML
Erythroid progenitors
Erythroid
HPC7
Macrophages
MEL
MK cells
MK progenitors
Myeloid progenitors
T cells
Thymocytes
739 Late Ery + T/B cell + GRAN TCF7
MXI1, NELFE
FLI1
RAG2
EML
MEL
T cells
Thymocytes
763 Late MYE EBF1
RUNX1, TCF7
PU1
FLI1, GFI1B, RUNX1, SCL
CEBPA, CEBPB, P65, PPARG, STAT1
NELFE
CBFB
GATA3, STAT4, TBET
RAG2
B cells
EML
Erythroid
HPC7
Macrophages
MEL
MK progenitors
T cells
Thymocytes
793 Late Ery + T/B – cell + GRAN TCF7
SCL
NELFE
ETS1, RUNX1
FLI1
CBFB, RAG2
EML
HPC
MEL
MK progenitors
T cells
Thymocytes
799 NK + T cells (2) E2A, FOX01, OCT2, PAX5, PU1
RUNX1
ETO2, PU1
GATA2, LDB1, SCL
ERG, FLI1, GATA2, GFI1B, LMO2, LYL1, MEIS1, PU1, RUNX1, SCL
CEBPA, CEBPB, P65, PPARG, PU1, STAT1
CMYB, CHD2, JUND
GATA1
CBFB, GATA1, GATA2, RING1B
MYB
SMAD1
FLI1, GATA3, PU1, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
CBFB, RAG2, RUNX1
B cells
EML
Erythroid
HPC
HPC7
Macrophages
MEL
MK cells
MK progenitors
Myeloid progenitors
Pro B cells
T cells
Thymocytes
811 Early Mye + T/B cell + GRAN TCF7
SCL
CMYC, MXI1, NELFE, TBP, USF2
ETS1, RUNX1
FLI1
RAG2, RUNX1
EML
HPC7
MEL
MK progenitors
T cells
Thymocytes
817 T/B cell E2A, EBF1, OCT2, PAX5
RUNX1, TCF7
ETO2, GFI1B, PU1, SCL
GATA2, SCL
ERG, FLI1, GFI1B, LMO2, MEIS1, PU1, RUNX1, SCL
CEBPA, CEBPB, P65, PPARG, STAT1
CMYB, CHD2, MXI1, NELFE, SCL
CBFB, GATA2, RING1B, RUNX1
EBF1, SMAD1
FLI1, GATA3, STAT3, STAT4, STAT5A, STAT5B
CBFB, RAG2, RING1B, RUNX1
B cells
EML
Erythroid
HPC
HPC7
Macrophages
MEL
MK progenitors
Pro B cells
T cells
Thymocytes
823 Early Mye + T/B cell + GRAN MXI1, NELFE
FLI1
RAG2
MEL
T cells
Thymocytes
835 Early Mye + T/B – cell + GRAN GFI1B
ERG
CMYC, CHD2, MAX, NELFE, TBP
ETS1, RUNX1
FLI1, STAT3, STAT6
RAG2
Erythroid
HPC7
MEL
MK progenitors
T cells
Thymocytes
841 Early Mye + T/B cell + GRAN TCF7
SCL
NOTCH1
CMYC, MAX, MXI1, NELFE, TBP
ETS1
FLI1
RAG2
EML
HPC7
Leukemia
MEL
MK progenitors
T cells
Thymocytes
859 T cell + NK RING1B Thymocytes
871 HSC + Early MYE MXI1, NELFE
FLI1
RAG2
MEL
T cells
Thymocytes
883 Late Ery + T/B cell + GRAN PU1
TCF7
GATA1
GATA1, GFI1B
ERG, SCL
CEBPB
CMYC, CHD2, MXI1, NELFE, TBP
CBFB, RING1B, RUNX1
FLI1, STAT3, STAT4, STAT5, STAT6, TBET
RAG2, RING1B, RUNX1
B cells
EML
Erythroid progenitors
Erythroid
HPC7
Macrophages
MEL
MK progenitors
T cells
Thymocytes
889 Late Ery GATA1, GATA2, SMAD1
ETO2, GATA1, LDB1, MTGR1, SCL
GATA2, LDB1, SCL
LMO2, RUNX1
CEBPA, CEBPB
CMYB, GATA1, MAFK, MAX, SCL, USF2
GATA1
GATA1, GATA2, RING1B, RUNX1
Erythroid progenitors
Erythroid
HPC
HPC7
Macrophages
MEL
MK cells
MK progenitors
901 Early Mye + T/B cell + GRAN TCF7
GFI1B
NOTCH1
CMYC, MXI1, NELFE, TBP
ETS1
FLI1, STAT5B
RAG2, RUNX1
EML
Erythroid
Leukemia
MEL
MK progenitors
T cells
Thymocytes
907 Late Ery + T/B cell + GRAN TCF7
GATA1, GATA2
ETO2, GATA1, GFI1B, MTGR1
LDB1, SCL
NOTCH1
CMYC, GATA1, MAX, MXI1, NELFE, SCL, TBP
CBFB, ETS1, GATA1, RING1B
FLI1, STAT3, STAT5B, STAT6, TBET
RAG2
EML
Erythroid progenitors
Erythroid
HPC
Leukemia
MEL
MK progenitors
T cells
Thymocytes
925 Early Mye + T/B cell + GRAN TCF7
CMYC, MXI1, NELFE, TBP
FLI1, STAT6
RAG2
EML
MEL
T cells
Thymocytes
943 T/B cell TCF7
NELFE
ETS1
FLI1
RAG2
EML
MEL
MK progenitors
T cells
Thymocytes
961 B cell E2A, EBF1, OCT2 B cells
973 HSE + Early Mye NELFE MEL
979 Late MYE CEBPA, CEBPB, P65, PPARG, STAT1
MYB
Macrophages
Myeloid progenitors
985 Early Mye + T/B – cell + GRAN CHD2 MEL
991 T/B cell E2A, OCT2, PAX5, PU1
RUNX1, TCF7
GATA1, GATA2
GATA1, GFI1B, PU1
ERG, FLI1, GFI1B, MEIS1, PU1
CEBPA, CEBPB, P65, PPARG, STAT1
CMYC, CHD2, MAX, MXI1, NELFE, TBP
CBFB, ETS1, RING1B, RUNX1
MYB
EBF1
FLI1, PU1, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
B cells
EML
Erythroid progenitors
Erythroid
HPC7
Macrophages
MEL
MK progenitors
Myeloid progenitors
Pro B cells
T cells
Thymocytes
1003 Late Ery + T/B – cell + GRAN NELFE
RAG2
MEL
Thymocytes
1021 Early Mye + T/B cell + GRAN TCF7
GFI1B
NELFE
ETS1
FLI1
RAG2, RING1B, RUNX1
EML
Erythroid
MEL
MK progenitors
T cells
Thymocytes

Supplementary Table 3.

Sixty-five gene sets of 80 with respective induction patterns from Novershtern et al. [14] enriched for transcription factor binding regions across multiple blood tissues using GSCA: 63 of 65 show cell type and induction pattern matching

Novershtern et al. clusters
Combinatorial control signature
No. Induction pattern Transcription factor Cell type
399 None STAT4, STAT5 T cells
559 NK + T cell (2) STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET T cells
571 Late MYE CEBPA, CEBPB, P65, PU1, STAT1 Macrophages
583 Late ERY + T/B cell + Gran GATA1, GATA2, SMAD1
SCL
SCL
MAX, MXI1, TBP
RAG2
Erythroid progenitors
Erythroid
HPC
MEL
Thymocytes
607 Early MYE + T/B cell + Gran PU1
ERG, FLI1, GFI1B, MEIS1, PU1, SCL
CEBPA, CEBPB, P65, PPARG, PU1, STAT1
MYB
GATA3, PU1, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
B cells
HPC7
Macrophages
Myeloid progenitors
T cells
613 T/B – cell PU1 B cells
619 Late MYE CEBPA, CEBPB, PU1, STAT1 Macrophages
637 Late Ery GATA1, GATA2, SMAD1
GATA1, LDB1, MTGR1, SCL
ERG, LDB1
ERG
GATA1, SCL
GATA1, RING1B, RUNX1
Erythroid progenitors
Erythroid
HPC
HPC7
MEL
MK progenitors
643 HSE + Early Mye GATA2 HPC7
649 B cells E2A, PAX5, PU1
CEBPA, CEBPB, P65, PU1, STAT1
B cells
Macrophages
655 Mye GATA1, GATA2, SMAD1
GATA1, LDB1, MTGR1, SCL
LDB1, SCL
CEBPB, P65, PU1, STAT1
CMYB, CMYC, GATA1, MAFK, MXI1, SCL, TBP
CBFB, GATA1, RING1B
Erythroid progenitors
Erythroid
HPC
Macrophages
MEL
MK progenitors
661 Late Ery + T/B cell + GRAN PU1
GATA1, GATA2
CMYB, CHD2, GATA1, MXI1, NELFE, TBP
ETS1
FLI1
RAG2
B cells
Erythroid progenitors
MEL
MK progenitors
T cells
Thymocytes
667 T cell + NK GATA3, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
CBFB, RAG2, RING1B, RUNX1
T cells
Thymocytes
673 T/B cell E2A, OCT2, PU1
CEBPB, P65, PU1, STAT1
GATA3, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
B cells
Macrophages
T cells
679 HSE + Early Mye GATA2 Erythroid progenitors
685 Late MYE + T/B cell + GRAN RUNX1, TCF7
GFI1B, PU1
ERG, PU1, SCL
CEBPA, CEBPB, P65, PU1, STAT1
CMYC, GATA1, MXI1, NELFE, TBP
CBFB, ETS1
FLI1, PU1
RAG2, RUNX1
EML
Erythroid
HPC7
Macrophages
MEL
MK progenitors
T cells
Thymocytes
703 T/B cell TCF7
GFI1B
ERG, PU1
NOTCH1
CMYC, MAX, MXI1, NELFE, TBP
CBFB, ETS1
FLI1, STAT3, STAT4, STAT5B, STAT6, TBET
CBFB, RAG2
EML
Erythroid
HPC7
Leukemia
MEL
MK progenitors
T cells
Thymocytes
709 General mild induction ETO2
AF9
Erythroid
MLL leukemia
715 Early MYE + T/B cell + GRAN PU1
TCF7
GFI1B
CEBPA, CEBPB, PU1, STAT1
CMYC, GATA1, MXI1, NELFE, TBP
ETS1
FLI1
RAG2
B cells
EML
Erythroid
Macrophages
MEL
MK progenitors
T cells
Thymocytes
721 Late MYE + DCs CEBPA, CEBPB, P65, PU1, STAT1
MYB
Macrophages
Myeloid progenitors
727 Late Ery GATA1, GATA2, SMAD1
ETO2, GATA1, GFI1B, LDB1, MTGR1, SCL
LDB1, SCL
CMYC, GATA1, MAFK, MAX, MXI1, SCL, TBP
CBFB, GATA1, GATA2, RING1B, RUNX1
Erythroid progenitors
Erythroid
HPC
MEL
MK progenitors
733 HSC + Early MYE CEBPA, CEBPB, P65, PU1, STAT1
MYB
Macrophages
Myeloid progenitors
739 Late ERY + T/B cell + Gran PU1
TCF7
GATA1, GATA2
GFI1B, PU1
ERG, PU1
NOTCH1
CMYC, CHD2, GATA1, MAX, MXI1, NELFE, TBP
CBFB, ETS1, RUNX1
FLI1
RAG2, RUNX1
B cells
EML
Erythroid progenitors
Erythroid
HPC7
Leukemia
MEL
MK progenitors
T cells
Thymocytes
745 General mild induction MYB
STAT3, STAT4, STAT5
Myeloid progenitors
T cells
757 T cell + NK TCF7
CMYC, MAX, MXI1, NELFE, TBP
FLI1, STAT3, STAT5, TBET
RAG2
EML
MEL
T cells
Thymocytes
763 Late MYE ERG, FLI1
CEBPA, CEBPB, P65, PPARG, PU1, STAT1
PU1, STAT3, STAT4, STAT5, TBET
HPC7
Macrophages
T cells
769 T/B cell PU1
CEBPA, CEBPB
GATA3, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
B cells
Macrophages
T cells
775 Mye GATA1 MK cells
781 General mild induction NOTCH1 TALL
787 MYE SMAD1
CEBPA, CEBPB, STAT1
GATA1, MAFK
Erythroid progenitors
Macrophages
MEL
793 Late ERY + T/B cell + Gran PAX5, PU1
TCF7
GATA1, GATA2, SMAD1
GATA1, PU1, SCL
PU1, SCL
PU1
CEBPA, CEBPB, PU1, STAT1
CMYB, CMYC, GATA1, MAX, MXI1, NELFE, SCL, TBP
GATA1
CBFB, ETS1, RING1B, RUNX1
FLI1, GATA3, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
CBFB, RAG2, RUNX1
B cells
EML
Erythroid progenitors
Erythroid
HPC
HPC7
Macrophages
MEL
MK cells
MK progenitors
T cells
Thymocytes
799 NK + T cell (2) E2A
CEBPA, CEBPB, P65, PU1, STAT1
GATA3, PU1, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
B cells
Macrophages
T cells
805 HSE + Early Mye ETO2 Erythroid
811 Late MYE + T/B cell + GRAN TCF7
GFI1B
ERG, SCL
CEBPA, CEBPB, PU1
CMYC, CHD2, MAX, MXI1, NELFE, TBP, USF2
CBFB, ETS1, RUNX1
FLI1, STAT4, STAT5B, STAT5, STAT6, TBET
CBFB, RAG2, RING1B, RUNX1
EML
Erythroid
HPC7
Macrophages
MEL
MK progenitors
T cells
Thymocytes
817 T/B cell E2A, EBF1, PAX5, PU1
ERG, MEIS1, PU1
CEBPA, CEBPB, P65, PPARG, PU1, STAT1
RING1B
EBF1, SMAD1
FLI1, PU1, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
CBFB, RAG2, RUNX1
B cells
HPC7
Macrophages
MK progenitors
Pro B cells
T cells
Thymocytes
823 Early MYE + T/B cell + GRAN TCF7
GATA2
GFI1B
SCL
NOTCH1
CMYC, CHD2, MAX, MXI1, NELFE, TBP
CBFB, ETS1
RBPJ
FLI1, STAT3, STAT6
RAG2
EML
Erythroid progenitors
Erythroid
HPC7
Leukemia
MEL
MK progenitors
T cell leukemia
T cells
Thymocytes
829 T cell + NK E2A
GATA3, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET
CBFB, RUNX1
B cells
T cells
Thymocytes
835 Early MYE + T/B cell + GRAN PAX5
TCF7
GFI1B
ERG
NOTCH1
CMYC, CHD2, MAX, MXI1, NELFE, TBP
CBFB, ETS1, RUNX1
RBPJ
FLI1
RAG2
B cells
EML
Erythroid
HPC7
Leukemia
MEL
MK progenitors
T cell leukemia
T cells
Thymocytes
841 Early MYE + T/B cell + GRAN PU1
TCF7
GFI1B, PU1
ERG, GFI1B, PU1, SCL
NOTCH1
PU1
CMYC, CHD2, MAX, MXI1, NELFE, TBP
ETS1, RUNX1
AF9
RBPJ
FLI1, PU1, STAT3, STAT4, STAT5B, STAT6, TBET
RAG2
B cells
EML
Erythroid
HPC7
Leukemia
Macrophages
MEL
MK progenitors
MLL leukemia
T cell leukemia
T cells
Thymocytes
847 Late Ery + T/B cell + GRAN PAX5
TCF7
GATA1, GFI1B
GFI1B
NOTCH1
CMYC, CHD2, MAX, MXI1, NELFE, TBP
CBFB, ETS1, RUNX1
RBPJ
FLI1, STAT3, STAT4, STAT5B, STAT6, TBET
RAG2
B cells
EML
Erythroid
HPC7
Leukemia
MEL
MK progenitors
T cell leukemia
T cells
Thymocytes
853 Late MYE PU1
ERG, PU1
CEBPA, CEBPB, P65, PU1, STAT1
PU1, STAT3, STAT4, STAT5A, STAT5, STAT6
B cells
HPC7
Macrophages
T cells
859 T cell + NK GATA3, STAT3, STAT5, TBET T cells
865 HSE + early Mye GATA2, SMAD1
GATA1
Erythroid progenitors
MEL
871 HSE + Early MYE TCF7
GFI1B
ERG, MEIS1, PU1
NOTCH1
CEBPA, CEBPB, PU1, STAT1
CMYC, MAX, MXI1, NELFE, TBP
CBFB
FLI1, STAT3, STAT6, TBET
RAG2
EML
Erythroid
HPC7
Leukemia
Macrophages
MEL
MK progenitors
T cells
Thymocytes
883 Late MYE + T/B cell + Gran TCF7
GATA1, GFI1B
SCL, SCL
SCL
CMYC, CHD2, MXI1, NELFE, TBP
RING1B, RUNX1
FLI1, STAT4, STAT6, TBET
RAG2, RUNX1
EML
Erythroid
HPC
HPC7
MEL
MK progenitors
T cells
Thymocytes
889 Late ERY GATA1, GATA2, SMAD1
ETO2, GATA1, LDB1, MTGR1, SCL
LDB1, SCL
GATA1, SCL
GATA1, GATA2, RING1B
STAT4
Erythroid progenitors
Erythroid
HPC
MEL
MK progenitors
T cells
895 Late ERY GATA2
GATA1, LDB1
CEBPA, CEBPB, PU1, STAT1
MXI1
Erythroid progenitors
Erythroid
Macrophages
MEL
901 Late MYE + T/B cell + Gran TCF7
GATA1, GATA2, SMAD1
GFI1B, PU1
GFI1B
NOTCH1
CMYC, GATA1, MAX, MXI1, NELFE, TBP
CBFB, ETS1
FLI1, STAT3, STAT5B, STAT5
CBFB, RAG2, RING1B, RUNX1
EML
Erythroid progenitors
Erythroid
HPC7
Leukemia
MEL
MK progenitors
T cells
Thymocytes
907 Late ERY + T/B cell + Gran PAX5, PU1
TCF7
GATA1, GATA2, SMAD1
ETO2, GATA1, GFI1B, LDB1, MTGR1, SCL
ERG, LDB1, SCL
ERG
NOTCH1
CMYB, CMYC, CHD2, GATA1, MAX, MXI1, NELFE, SCL, TBP
CBFB, ETS1, GATA1, RING1B, RUNX1
FLI1
RAG2
B cells
EML
Erythroid progenitors
Erythroid
HPC
HPC7
Leukemia
MEL
MK progenitors
T cells
Thymocytes
919 HSE + Early Mye FOX01
ERG
CMYC, MXI1, NELFE, TBP
B cells
HPC7
MEL
925 Early MYE + T/B cell + GRAN PAX5, PU1
TCF7
GATA1, GATA2, SMAD1
GATA1, GFI1B, PU1
ERG, SCL, SCL
ERG, SCL
CMYC, CHD2, GATA1, MAX, MXI1, NELFE, SCL, TBP
CBFB, ETS1, RING1B, RUNX1
FLI1, STAT3, STAT4, STAT5B, STAT5, STAT6, TBET
RAG2, RING1B
B cells
EML
Erythroid progenitors
Erythroid
HPC
HPC7
MEL
MK progenitors
T cells
Thymocytes
931 None GATA1
STAT4, STAT5B, STAT5
MEL
T cells
943 T/B cell TCF7
GATA2
PU1
CMYC, MXI1, NELFE, TBP
ETS1
FLI1, GATA3, STAT3, STAT4, STAT5B, STAT5, STAT6, TBET
CBFB, RAG2, RUNX1
EML
Erythroid progenitors
Erythroid
MEL
MK progenitors
T cells
Thymocytes
949 T/B cell GATA2
RAG2
Erythroid progenitors
Thymocytes
955 T cell + NK GATA3, STAT3, STAT4, STAT5A, STAT5B, STAT5, STAT6, TBET T cells
961 B cell E2A, EBF1, OCT2, PAX5, PU1
CEBPA, CEBPB, P65, PU1, STAT1
B cells
Macrophages
967 Late ERY + T/B cell + Gran PAX5
TCF7
GATA1, GFI1B, LDB1
ERG, FLI1, MEIS1, PU1, SCL
NOTCH1
CMYC, CHD2, MAX, MXI1, NELFE, SMC3, TBP
CBFB, ETS1, RING1B, RUNX1
FLI1, STAT4, STAT6, TBET
RAG2
B cells
EML
Erythroid
HPC7
Leukemia
MEL
MK progenitors
T cells
Thymocytes
973 HSE + Early Mye CMYC, GATA1, MAX, MXI1 MEL
979 Late MYE PU1
GFI1B
CEBPA, CEBPB, P65, PPARG, PU1, STAT1
EBF1
STAT3, STAT4, STAT5, STAT6
B cells
HPC7
Macrophages
Pro B cells
T cells
985 Early MYE + T/B cell + Gran TCF7
GFI1B
ERG, SCL
CMYC, CHD2, MAX, MXI1, NELFE, TBP
ETS1, RUNX1
FLI1, STAT3, STAT4, STAT6, TBET
CBFB, RAG2, RUNX1
EML
Erythroid
HPC7
MEL
MK progenitors
T cells
Thymocytes
991 T/B cell PU1
GATA2
PU1
ERG
CEBPA, CEBPB, PU1, STAT1
MXI1, TBP
FLI1, STAT3, STAT4, STAT5B, STAT5, STAT6, TBET
RAG2
B cells
Erythroid progenitors
Erythroid
HPC7
Macrophages
MEL
T cells
Thymocytes
997 NK + T cell (2) STAT4 T cells
1003 Late ERY + T/B cell + Gran TCF7
GATA1, GFI1B, PU1, SCL
ERG, PU1, SCL
ERG, PU1
NOTCH1
CMYC, CHD2, MAX, MXI1, NELFE, TBP
CBFB, ETS1, RING1B, RUNX1
RBPJ
FLI1, GATA3, STAT3, STAT6
CBFB, RAG2, RING1B, RUNX1
EML
Erythroid
HPC
HPC7
Leukemia
MEL
MK progenitors
T cell leukemia
T cells
Thymocytes
1009 HSE + Early Mye CEBPA, CEBPB, P65, PU1, STAT1 Macrophages
1021 Early MYE + T/B cell + GRAN PAX5
TCF7
GATA1
GFI1B, PU1
SCL
NOTCH1
CMYC, CHD2, MXI1, NELFE, TBP
ETS1, RUNX1
FLI1
RAG2, RING1B, RUNX1
B cells
EML
Erythroid progenitors
Erythroid
HPC7
Leukemia
MEL
MK progenitors
T cells
Thymocytes

References

  • 1.Graf T., Enver T. Forcing cells to change lineages. Nature. 2009;462:587–594. doi: 10.1038/nature08533. [DOI] [PubMed] [Google Scholar]
  • 2.Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132:631–644. doi: 10.1016/j.cell.2008.01.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ye M., Graf T. Early decisions in lymphoid development. Curr Opin Immunol. 2007;19:123–128. doi: 10.1016/j.coi.2007.02.007. [DOI] [PubMed] [Google Scholar]
  • 4.Nerlov C., Graf T. Pu.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev. 1998;12:2403–2412. doi: 10.1101/gad.12.15.2403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Laslo P., Spooner C.J., Warmflash A. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell. 2006;126:755–766. doi: 10.1016/j.cell.2006.06.052. [DOI] [PubMed] [Google Scholar]
  • 6.McNagny K.M. Regulation of eosinophil-specific gene expression by a c/ebp-ets complex and gata-1. EMBO J. 1998;17:3669–3680. doi: 10.1093/emboj/17.13.3669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Johnson D.S., Mortazavi A., Myers R.M., Wold B. Genome-wide mapping of in vivo protein-dna interactions. Science. 2007;316:1497–1502. doi: 10.1126/science.1141319. [DOI] [PubMed] [Google Scholar]
  • 8.Hannah R., Joshi A., Wilson N.K., Kinston S., Göttgens B. A compendium of genome-wide hematopoietic transcription factor maps supports the identification of gene regulatory control mechanisms. Exp Hematol. 2011;39:531–541. doi: 10.1016/j.exphem.2011.02.009. [DOI] [PubMed] [Google Scholar]
  • 9.Ashburner M., Ball C.A., Blake J.A. Gene ontology: tool for the unification of biology. the gene ontology consortium. Nat Genet. 2000;25:25–29. doi: 10.1038/75556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2008;4:44–57. doi: 10.1038/nprot.2008.211. [DOI] [PubMed] [Google Scholar]
  • 11.Subramanian A. From the cover: gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wilson N.K., Foster S.D., Wang X. Combinatorial transcriptional control in blood stem/progenitor cells: Genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell. 2010;7:532–544. doi: 10.1016/j.stem.2010.07.016. [DOI] [PubMed] [Google Scholar]
  • 13.Pennacchio L.A., Loots G.G., Nobrega M.A., Ovcharenko I. Predicting tissue-specific enhancers in the human genome. Gen Res. 2007;17:201–211. doi: 10.1101/gr.5972507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Novershtern N., Subramanian A., Lawton L.N. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011;144:296–309. doi: 10.1016/j.cell.2011.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ng S.Y.-M., Yoshida T., Zhang J., Georgopoulos K. Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity. 2009;30:493–507. doi: 10.1016/j.immuni.2009.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhao L., Glazov E.A., Pattabiraman D.R. Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by myb. Nucleic Acids Res. 2011;39:4664–4679. doi: 10.1093/nar/gkr024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Yu M., Mazor T., Huang H. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell. 2012;45:330–343. doi: 10.1016/j.molcel.2011.11.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wei G., Abraham B.J., Yagi R. Genome-wide analyses of transcription factor gata3-mediated gene regulation in distinct t cell types. Immunity. 2011;35:299–311. doi: 10.1016/j.immuni.2011.08.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wang H., Zou J., Zhao B. Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc Natl Acad Sci U S A. 2011;108:14908–14913. doi: 10.1073/pnas.1109023108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Trowbridge J.J., Sinha A.U., Zhu N. Haploinsufficiency of dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 2012;26:344–349. doi: 10.1101/gad.184341.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Trompouki E., Bowman T.V., Lawton L.N. Lineage regulators direct bmp and wnt pathways to cell-specific programs during differentiation and regeneration. Cell. 2011;147:577–589. doi: 10.1016/j.cell.2011.09.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Treiber T., Mandel E.M., Pott S. Early B cell factor 1 regulates B cell gene networks by activation, repression, and transcription-independent poising of chromatin. Immunity. 2010;32:714–725. doi: 10.1016/j.immuni.2010.04.013. [DOI] [PubMed] [Google Scholar]
  • 23.Ntziachristos P., Tsirigos A., Van Vlierberghe P. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012;18:298–301. doi: 10.1038/nm.2651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ng S.-L., Friedman B.A., Schmid S. Iκb kinase epsilon (ikk(epsilon)) regulates the balance between type I and type II interferon responses. Proc Natl Acad Sci U S A. 2011;108:21170–21175. doi: 10.1073/pnas.1119137109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Nakayamada S., Kanno Y., Takahashi H. Early Th1 cell differentiation is marked by a Tfh cell-like transition. Immunity. 2011;35:919–931. doi: 10.1016/j.immuni.2011.11.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Mullen A.C., Orlando D.A., Newman J.J. Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell. 2011;147:565–576. doi: 10.1016/j.cell.2011.08.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Li L., Jothi R., Cui K. Nuclear adaptor ldb1 regulates a transcriptional program essential for the maintenance of hematopoietic stem cells. Nat Immunol. 2011;12:129–136. doi: 10.1038/ni.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Choe K.S., Ujhelly O., Wontakal S.N., Skoultchi A.I. Pu.1 directly regulates cdk6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells. J Biol Chem. 2009;285:3044–3052. doi: 10.1074/jbc.M109.077727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bernt K.M., Zhu N., Sinha A.U. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20:66–78. doi: 10.1016/j.ccr.2011.06.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wontakal S.N., Guo X., Smith C. A core erythroid transcriptional network is repressed by a master regulator of myelo-lymphoid differentiation. Proc Natl Acad Sci U S A. 2012;109:3832–3837. doi: 10.1073/pnas.1121019109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Vilagos B., Hoffmann M., Souabni A. Essential role of Ebf1 in the generation and function of distinct mature B cell types. J Exp Med. 2012;209:775–792. doi: 10.1084/jem.20112422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Wu J.Q., Seay M., Schulz V.P. Tcf7 is an important regulator of the switch of self-renewal and differentiation in a multipotential hematopoietic cell line. PLoS Genet. 2012;8:e1002565. doi: 10.1371/journal.pgen.1002565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zhang Z.-Y., Li T., Ding C., Ren X.-W., Zhang X.-S. Binary matrix factorization for analyzing gene expression data. Data Min Knowl Disc. 2009;20:28–52. [Google Scholar]
  • 34.Lachmann A., Xu H., Krishnan J. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics. 2010;26:2438–2444. doi: 10.1093/bioinformatics/btq466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zambelli F., Prazzoli G.M., Pesole G., Pavesi G. Cscan: finding common regulators of a set of genes by using a collection of genome-wide ChIP-Seq datasets. Nucleic Acids Res. 2012;40:W510–W515. doi: 10.1093/nar/gks483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Segal E., Shapira M., Regev A. Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat Genet. 2003;34:166–176. doi: 10.1038/ng1165. [DOI] [PubMed] [Google Scholar]
  • 37.McLean C.Y., Bristor D., Hiller M. Great improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010;28:495–501. doi: 10.1038/nbt.1630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ford A.M., Bennett C.A., Healy L.E. Immunoglobulin heavy-chain and CD3 delta-chain gene enhancers are DNAase I-hypersensitive in hemopoietic progenitor cells. Proc Natl Acad Sci U S A. 1992;89:3424–3428. doi: 10.1073/pnas.89.8.3424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.McCormack M.P., Young L.F., Vasudevan S. The lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science. 2010;327:879–883. doi: 10.1126/science.1182378. [DOI] [PubMed] [Google Scholar]
  • 40.Zuber J., Rappaport A.R., Luo W. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25:1628–1640. doi: 10.1101/gad.17269211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Baudino T.A., Cleveland J.L. The max network gone mad. Mol Cell Biol. 2001;21:691–702. doi: 10.1128/MCB.21.3.691-702.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Somervaille T.C.P., Matheny C.J., Spencer G.J. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell. 2009;4:129–140. doi: 10.1016/j.stem.2008.11.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kim J., Woo A.J., Chu J. A myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010;143:313–324. doi: 10.1016/j.cell.2010.09.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Park P.J. ChIP-Seq: advantages and challenges of a maturing technology. Nat Rev Genet. 2009;10:669–680. doi: 10.1038/nrg2641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Wilson N.K., Tijssen M.R., Göttgens B. Deciphering transcriptional control mechanisms in haematopoiesis—the impact of high-throughput sequencing technologies. Exp Hematol. 2011;39:961–968. doi: 10.1016/j.exphem.2011.07.005. [DOI] [PubMed] [Google Scholar]
  • 46.Suzuki H., Forrest A.R.R., van Nimwegen E. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet. 2009;41:553–562. doi: 10.1038/ng.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Wilson M.D., Odom D.T. Evolution of transcriptional control in mammals. Curr Opin Genet Dev. 2009;19:579–585. doi: 10.1016/j.gde.2009.10.003. [DOI] [PubMed] [Google Scholar]
  • 48.Roy S., Ernst J., Kharchenko P.V. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science. 2010;330:1787–1797. doi: 10.1126/science.1198374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Celniker S.E., Dillon L.A.L., Gerstein M.B. Unlocking the secrets of the genome. Nature. 2009;459:927–930. doi: 10.1038/459927a. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES